Phenotypes associated with this allele

• Allele Symbol: Map3k8^tm1.2Gkl
• Allele Name: targeted mutation 1.2, George Kollias
• Allele ID: MGI:5476711
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Map3k8^tm1.2Gkl/Map3k8^tm1.2Gkl	involves: 129 * C57BL/6J * FVB/N	MGI:5476716

Genotype
MGI:5476716

hm1

• Allelic Composition: Map3k8^tm1.2Gkl/Map3k8^tm1.2Gkl
• Genetic Background: involves: 129 * C57BL/6J * FVB/N

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:193546 )

• mice are resistant to LPS/D-galactosamine lethality

increased susceptibility to xenobiotic induced morbidity/mortality ( J:193546 )

• in mice treated with AOM/DSS

digestive/alimentary system

rectal hemorrhage ( J:193546 )

• in mice treated with AOM/DSS

decreased enterocyte apoptosis ( J:193546 )

• decreased in mice treated with AOM/DSS

abnormal enterocyte proliferation ( J:193546 )

• increased in mice treated with AOM/DSS

abnormal colon morphology ( J:193546 )

• high-grade dysplasia in mice treated with AOM/DSS

decreased colon length ( J:193546 )

• decreased colon length in mice treated with AOM/DSS

diarrhea ( J:193546 )

• in mice treated with AOM/DSS

neoplasm

increased incidence of tumors by chemical induction ( J:193546 )

• increased number and size of macroscopically visible tumors in mice treated with AOM/DSS

• however, treatment with only AOM does not alter tumor formation and inhibition of c-Met activation alleviates tumor promotion

increased tumor growth/size ( J:193546 )

• increased number of macroscopically visible tumors in mice treated with AOM/DSS

• however, treatment with only AOM does not alter tumor formation

cardiovascular system

rectal hemorrhage ( J:193546 )

• in mice treated with AOM/DSS

growth/size/body

increased susceptibility to weight loss ( J:193546 )

• in mice treated with AOM/DSS

homeostasis/metabolism

decreased susceptibility to xenobiotic induced morbidity/mortality ( J:193546 )

• mice are resistant to LPS/D-galactosamine lethality

increased susceptibility to xenobiotic induced morbidity/mortality ( J:193546 )

• in mice treated with AOM/DSS

increased physiological sensitivity to xenobiotic ( J:193546 )

• mice treated with AOM/DSS exhibit increased weight loss, decreased survival, increased disease index (diarrhea and rectal bleeding scores), high-grade colon dysplasia, decreased colon length and increased size and number of macroscopically visible tumors compared with wild-type mice

increased incidence of tumors by chemical induction ( J:193546 )

• increased number and size of macroscopically visible tumors in mice treated with AOM/DSS

• however, treatment with only AOM does not alter tumor formation and inhibition of c-Met activation alleviates tumor promotion

immune system

decreased tumor necrosis factor secretion ( J:193546 )

• in peritoneal macrophages tested with LPS

cellular

decreased enterocyte apoptosis ( J:193546 )

• decreased in mice treated with AOM/DSS

abnormal enterocyte proliferation ( J:193546 )

• increased in mice treated with AOM/DSS